I know we have covered the HepC trial results from 2024 before, but I am still curious (as I was back then) why BIT did not push forward to a commercial deal at the time.
I seem to recall that BIT wanted too much for the product and another company commercialised a competing product 6 months later.
Could anyone shed any light on what happened? Seems like a colossal lost opportunity.
Biotron shares soar on Hepatitis C trial data
Australian drug developer Biotron may have found a potential cure for Hepatitis C, after all patients who completed a trial of its lead antiviral drug emerged with undetectable levels of the virus.
UpdatedOct 10, 2014 – 2.59pm,first published at1.43pm
Australian drug developer Biotron may have found a potential cure for Hepatitis C.
Biotron said on Friday that all patients who completed a phase II clinical trial of its lead antiviral drug, BIT225, had undetectable levels of Hepatitis C after ceasing all treatment.
(20min delay)